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Clinical applications of PD-L1 bioassays for
cancer immunotherapy
Delong Liu1* , Shuhang Wang2 and Wendy Bindeman3
Abstract
Programmed death ligand 1 (PD-L1) has emerged as a biomarker that can help to predict responses to
immunotherapies targeted against PD-L1 and its receptor (PD-1). Companion tests for evaluating PD-L1 expression
as a biomarker of response have been developed for many cancer immunotherapy agents. These assays use a
variety of detection platforms at different levels (protein, mRNA), employ diverse biopsy and surgical samples, and
have disparate positivity cutoff points and scoring systems, all of which complicate the standardization of clinical
decision-making. This review summarizes the current understanding and ongoing investigations regarding PD-L1
expression as a potential biomarker for clinical outcomes of anti-PD-1/PD-L1 immunotherapy.
Background
Novel therapeutics targeting immune checkpoints are
leading to a fast and profound paradigm shift in cancer
therapy [1–3]. Durable responses to agents targeting
programmed cell death-1 protein receptor (PD-1) and
the ligand (PD-L1) have been observed in lung cancer as
well as a variety of cancer types [4–10]. PD-L1 expres-
sion varies due to the dynamic tumor microenvironment
[11–15]. No consensus has been reached on whether
PD-L1 expression can serve as a reliable biomarker for
patient selection in all cancer types. The assessment for
PD-L1 expression is becoming routine for many cancer
specimens, though how to employ the results remains a
clinical challenge. This article reviews existing data of
PD-L1 expression status and its predictive and prognos-
tic role in lung cancer and makes recommendations for
improving clinical interpretations.
Bioassays for PD-L1 expression
A companion diagnostic is necessary for the safe and
efficacious use of a corresponding drug or biological
product, whereas a complementary diagnostic identifies,
though not essential, a biomarker that can assist in the
risk/benefit assessment for a subset of patients who re-
spond to the corresponding drug differentially [16, 17].
Currently, the US Food and Drug Administration (FDA)
has approved four immunohistochemistry (IHC)-based
assays using diagnostic monoclonal antibodies, 22C3,
28-8, SP142, and SP263, to detect PD-L1 expression and
aid in clinical applications of corresponding drugs
(Table 1) [18–20]. 22C3 is the mouse hybridoma clone
22C3 monoclonal antibody (IgG1k) against the extracel-
lular domain of human PD-L1 (Phe19-Thr239) [21]. In
Western blotting, the 22C3 antibody labels a 40-kDa
protein band which corresponds to the recombinant hu-
man PD-L1 protein. 28-8 is a hybridoma clone generated
after immunization of rabbits with the extracellular do-
main of human PD-L1 (Phe19-Thr239) [22]. This clone
was screened by IHC using control cell lines with or
without expression of huPD-L1 or huPD-L2 and human
normal and tumor specimens with and without PD-L1
expression. The stable transfectant monoclonal anti-PD-
L1 clone 28-8 was produced for the PD-L1 IHC assay.
Notably, PD-L1 IHC 22C3 pharmDx and IHC 28-8
pharmDx are the first two FDA-approved assay systems
for qualitative detection of PD-L1 protein in formalin-
fixed, paraffin-embedded (FFPE) tissue. The level of PD-
L1 protein expression is determined by using tumor
proportion score (TPS) [22, 23]. The TPS score is the
percentage of tumor cells showing partial or complete
membrane staining at any intensity. Positive PD-L1
expression is defined as TPS ≥1%, and a specimen is
considered to have high PD-L1 expression if TPS ≥50%.
The third FDA-approved antibody, SP142, is a rabbit
monoclonal antibody against PD-L1 [24, 25]. This anti-
body has been validated and approved for use in the
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complementary assay kit, Ventana PD-L1 (SP142), to de-
tect PD-L1 expression and guide clinical therapy with
atezolizumab for advanced urothelial carcinoma and
non-small cell lung cancer (NSCLC) [26–29]. The com-
plementary assay considers PD-L1 expression levels
(level 1, 2, or 3) in both tumor cells (TC; 1/2/3) and im-
mune cells (IC; 1/2/3) for positivity. Various combina-
tions of TC and IC expression levels were used to define
positivity (cutoff values) in the clinical trials [27, 30–32].
The fourth PD-L1 antibody, SP263, was just approved
as a complementary diagnostic for durvalumab. SP263 is
a rabbit anti-human PD-L1 monoclonal antibody di-
rected against the cytoplasmic region of human PD-L1
[33] that has been optimized and validated for use with
FFPE NSCLC and HNSCC tissue samples. The antibody
SP263 is approved for qualitative detection of PD-L1
protein in FFPE NSCLC and other tissues. Clinical cutoff
values have been validated in clinical trials for guiding
the use of durvalumab (NCT01693562) [18, 34].
Recently, studies have also analyzed the PD-L1 expres-
sion at the genetic level. PD-L1 and PD-1 protein
expression were analyzed in 94 clinical cases of small
cell neuroendocrine carcinomas by IHC using two differ-
ent monoclonal antibodies (5H1, E1L3N). RNA-seq was
used to profile messenger RNA (mRNA) expression in
43 clinical cases. Results showed that RNA-seq yielded
highly comparable results with IHC and even more PD-
L1-positive cases than IHC; therefore, RNA-seq is also
suitable for detection of PD-L1 expression [35]. This
study also showed that the carcinoma cells were negative
for PD-L1 expression in all cases, and PD-L1 was de-
tected in tumor-infiltrating macrophages and lympho-
cytes. Another study examined 133 cases of lung
adenocarcinoma surgical samples and found that the
PD-L1 expression rate was 16.5% at the mRNA level and
13.5% at the protein level [36]. These two levels are
highly concordant (Kappa = 0.824), suggesting the feasi-
bility of using mRNA level as a biomarker for PD-L1
expression. Another study analyzed DNA copy number
and mRNA expression of PD-L1 in 335 patients with
soft tissue sarcomas (STS) by utilizing the sarcoma data
set of The Cancer Genome Altas (TCGA) and an
independent cohort of untreated high-grade STS [37].
This analysis showed that PD-L1copy number and ele-
vated mRNA expression have prognostic significance.
PD-L1 expression and cutoff values
So far, analysis of the relationship between PD-L1
expression and response to anti-PD-1/PD-L1 agents has
yielded promising results. One pooled analysis summa-
rized data from seven studies with 914 NSCLC patients
[38]. Patients with TC staining ≥1% were considered PD-
L1-positive. These patients had a significantly higher
objective response rate (ORR) than those with PD-L1-
negative tumors. Further, the PD-L1 threshold of ≥1%
and higher positivity (5 and 50%) has been correlated
with responses in a meta-analysis [39]. The higher the
PD-L1 expression in the specimens, the higher the clin-
ical ORR to the anti-PD-1/PD-L1 agents. In another
meta-analysis of 13 studies with 1979 NSCLC patients,
ORR correlation with PD-L1 expression levels assayed
with several antibodies (DAKO 28-8, DAKO 22C3, VEN-
TANA SP 142) were compared. The ORR generally
increased with the level of PD-L1 expression increasing
from 1, 5, 10, 25, 50 to 75% [40]. In summary, currently
available data support the hypothesis that tumor PD-L1
positivity is a useful biomarker for predicting patient
response to anti-PD-1/PD-L1 agents.
An ongoing challenge to the application of PD-L1 bio-
marker assays in clinic is that each anti-PD1/PD-L1
agent has its own companion assay. These assays have
not been standardized for all the agents and therefore
are not interchangeable. However, several groups have
examined the degree of agreement between different
methods. One large study of 493 samples compared the
extent of concordance among three validated, commer-
cially available PD-L1 IHC assays (Ventana SP263, Dako
22C3, and Dako 28-8) for NSCLC patients and found an
overall percentage agreement of >90% between assays.
These assays were also consistent at multiple expression
cutoffs, including 1, 10, 25, and 50% tumor cell mem-
brane staining [41]. Most recently, Gaule et al. assessed
PD-L1 expression using six monoclonal antibodies
(SP142, E1L3N, 9A11, SP263, 22c3, and 28-8) on a
Table 1 PD-L1 immunohistochemistry assays for clinical application
Agent Nivolumab Pembrolizumab Atezolizumab Durvalumab
Antibody 28-8 22C3 SP142 SP263
Isotype and host species Rabbit IgG Mouse IgG Rabbit IgG Rabbit IgG
Binding site Extracellular Extracellular Intracellular Intracellular
Cell scored Tumor cell Tumor cell Tumor cell Tumor cell
Tumor stroma Immune cell
Cutoffs 1, 5, or ≥10% ≥50% tumor cell 1, 5, or ≥10% ≥25%
≥1% stroma
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genetically defined PD-L1 engineered cell line array with
a range of controlled protein-expressing cell lines. They
found that all six antibody reagents had high levels of
concordance in this IHC standardization study [42, 43].
This study further suggested that differences in PD-L1
expression in tissues as described in the previous studies
were independent of the antibody used. Rather, the dif-
ferences were attributed to the tumor heterogeneity,
assay-, or platform-specific variables.
Factors affecting bioassays for PD-L1 expression
PD-L1 expression is commonly focal and primarily iden-
tified at the tumor–stromal interface [44] and appears to
be highly heterogeneous. Additionally, PD-L1 expression
detection can be limited by the size and position of the
biopsy specimen and therefore provides only a snapshot
of the expression status of a tumor.
One study examined PD-L1 expression with the SP142
IHC assay in both whole surgical tissue sections and
matched lung biopsies from 160 patients with operable
NSCLC. PD-L1 expression was assayed in both TC and
IC cells. The study found that PD-L1 expression be-
tween the surgically resected and matched biopsy speci-
mens frequently disagree with each other (overall
discordance rate = 48%, κ = 0.218 [poor agreement]) [45].
The PD-L1 assay underestimated the expression from
larger resected tumor specimens. The rate of discord-
ance was inversely proportional to the number of cores
obtained. Sampling error is therefore a significant issue
in the detection of PD-L1, and a single biopsy specimen
with few cores may not accurately reflect the PD-L1
status of a tumor. This report is contradicted by another
study which retrospectively compared small biopsy sam-
ples with resected specimens from 79 NSCLC patients.
This latter study found that the positivity rate of PD-L1
assessed by IHC in the biopsy samples was 38.0 versus
35.4% in the resected specimens. This group found a
concordance rate of 92.4% and κ value of 0.8366, sug-
gesting that there is good concordance and adequate
assessment for PD-L1 expression with small samples
[46]. These retrospective studies and others are limited
in relatively small sample sizes [45–47].
In addition to the focal, heterogeneous expression of
PD-L1 within a single lesion, separate lesions from the
same patient may have different intensities and patterns
of PD-L1 expression. One study performed quantitative
assessment of the heterogeneity of PD-L1 expression in
49 NSCLC whole tissue sections and a corresponding
tissue microarray. Two rabbit monoclonal antibodies
(E1L3N and SP142) were used for both conventional
IHC and quantitative immunofluorescence (QIF).
Results showed that assessment of 588 serial section
fields of view by QIF exhibited a discordant expression
at a frequency of 25% [44].
In addition, PD-L1 expression varies among TC, IC,
and immune stroma in a given patient. Using 67 fully
resected, multifocal specimens from 32 NSCLC patients
to assess intertumoral heterogeneity, Mansfield et al.
reported that there was poor agreement of PD-L1
expression between paired lesions of 20 patients by
tumor and immune cells [48]. Although expression of
PD-L1 is heterogeneous among paired independent lung
cancers, this study showed that there are high levels of
agreement in intrapulmonary metastasis.
PD-L1 expression in TCs and ICs were examined in a
separate study which reported that PD-L1-positive TCs
were negatively correlated with PD-L1-positive ICs
within tumor stroma. In this analysis of 105 patients
with resected stage I pulmonary squamous cell carcin-
oma, tumor PD-L1 expression and increased CD4+ T
cell infiltrations in tumor stroma were found to be
independent predictors of better overall survival [49].
Therefore, different components of tumor and immune
microenvironment may play variable roles in modulation
of responses to cancer immunotherapy.
The heterogeneity also exists among primary, meta-
static, and transformed tumors. One study reported a
case of NSCLC who was found to have also small cell
lung cancer (SCLC) transformation in the lung and liver
metastasis at autopsy. The PD-L1 protein was partially
expressed in tumor cells with adenocarcinoma histology
but not in tumor cells from SCLC transformation [50].
Another study analyzed paired untreated primary lung
cancer and metastasis tissues from 98 postmortem cases
by microarray to evaluate the heterogeneity of PD-L1
expression and correlated with clinicopathological fea-
tures [51]. The study found that intratumoral heterogen-
eity in NSCLC is common (discordance rate 82%
between primary and metastatic tissues), while PD-L1
expression was undetectable in both primary and meta-
static SCLC tissues.
Taken together, these studies suggest that the results
of PD-L1 expression assays are affected by a variety of
factors, including specimen size, biopsy location, variable
components of tumor and immune microenvironment,
and tumor transformation. These factors should be
carefully considered when employing PD-L1 as a
predictive biomarker in clinical practice.
Clinical implications of soluble PD-L1
Several members of B7 family have been found to have
soluble counterparts [52–54]. Using ELISA, a soluble
form of PD-L1 (sPD-L1) has been detected in the sera of
patients [55]. The study showed that circulating sPD-L1
in human sera is involved in modulating immune
response. It has been further suggested that upregulation
of sPD-L1 production is associated with tumor-inspired
immune suppression and the poor prognosis [56–58]. In
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another study of 96 patients with lung cancer (85
NSCLC, 7 SCLC), sPD-L1 was detected by ELISA [59].
High sPD-L1 levels (≥7.32 ng/ml) were associated with
poor prognosis (high vs low sPD-L1: OS 13.0 vs
20.4 months, p = 0.037) in these patients [59]. It remains
unclear whether sPD-L1 level has correlation with
clinical response to the checkpoint inhibitor treatment.
Liquid biopsy is increasingly used as a substitute of
tissue sampling [60–62]. sPD-L1 deserves further inves-
tigation to see whether it can be used to guide clinical
decisions on choice of immunotherapeutic agents.
Conclusions
Novel therapeutics targeting immune checkpoints are
leading to a fast and profound paradigm shift in cancer
therapy. PD-L1 expression is a valuable biomarker to
guide clinical decisions. PD-L1 expression assays are
affected by a variety of factors, including specimen size,
biopsy location, variable components of tumor and im-
mune microenvironment, and tumor transformation.
These factors should be carefully considered when
employing PD-L1 as a predictive biomarker in clinical
practice. Future investigations should focus on standard-
izing detection, developing reliable methods of liquid
biopsy, and developing multiparameter quantitative or
semi-quantitative biomarker panels to provide clinicians
a more comprehensive understanding of the tumor and
immune microenvironment. Correlation of PD-L1
expression and tyrosine kinase biomarkers should also
be explored [63].
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